Independent lab results demonstrate that the combination therapy retains neutralizing activity agai...
The partnership will accelerate stockpiling, channel distribution and hospital access for the amuba...
Strategic executive hire adds to Company's global leadership team and positions the Company for con...
The Company is working closely with its commercial partners to supply the combination therapy to pa...
Exclusive development and commercialization rights to VIR-3434 in China strengthen Company's leader...
Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable...
DURHAM, N.C. and BEIJING, May 25, 2022 /PRNewswire/ -- Brii Biosciences Limited
2022-05-25 08:00
4274
* Studies conducted by independent labs demonstrate the amubarvimab/romlusevimab combination reta...
DURHAM, N.C. and BEIJING, May 7, 2022 /PRNewswire/ -- Brii Biosciences Limited
2022-05-07 09:00
4859
New data demonstrate BRII-835 (VIR-2218) was well tolerated with notable reductions in serum HBsAgo...
DURHAM, N.C. and BEIJING, March 30, 2022 /PRNewswire/ -- Brii Biosciences
Limited
2022-03-30 08:05
2419
– Advancing key programs in HBV, CNS, and HIV – – Received first BLA approval for COVID-19 Treatme...
The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 ta...
DURHAM, N.C. and BEIJING, Jan. 27, 2022 /PRNewswire/ -- Brii Biosciences
2022-01-27 21:00
2899
DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-27 18:45
2988
DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-12 18:50
3358
The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment i...
DURHAM, N.C. and BEIJING, Dec. 6, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-06 10:54
2650
DURHAM, N.C. and BEIJING, Nov. 19, 2021 /PRNewswire/ -- Brii Biosciences
2021-11-19 19:06
2984
BEIJING and DURHAM, N.C., Nov. 17, 2021 /PRNewswire/ -- Brii Biosciences Limited
2021-11-17 18:52
2678